- info@anseaconsulting.com
- Singapore: +65 6956 6164
- Basel: +41 61 564 1420
Menu
To assess the pricing opportunity, business potential and overall China business case for a rare disease product (hormonal therapy) for a Pharma multinational
Pricing potential, reimbursement feasibility assessment, patient uptake & revenue potential at different price points, to determine go no-go decision for China.
Secondary research & primary interviews with KOL/payors in China
Pricing analysis, 10yrs patient & revenue model and overall P&L for commercial launch
in China, with estimates for registration & reimbursement times in different scenarios
Business case finalized with high confidence level from the internal project team to get management approval by end 2020 and decision to go-ahead for submission & launch in China
